These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38698580)

  • 41. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh.
    Alam S; Gupta UD; Alam M; Kabir J; Chowdhury ZR; Alam AK
    Indian J Gastroenterol; 2014 Sep; 33(5):452-7. PubMed ID: 25023045
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease.
    Kim D; Kim W; Joo SK; Kim JH; Harrison SA; Younossi ZM; Ahmed A
    Liver Int; 2019 Feb; 39(2):332-341. PubMed ID: 30298568
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Control of prolactin secretion.
    Benker G; Jaspers C; Häusler G; Reinwein D
    Klin Wochenschr; 1990 Dec; 68(23):1157-67. PubMed ID: 2126309
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Letter to the Editor: Nonalcoholic Fatty Liver Disease Without Metabolic-Associated Fatty Liver Disease and Metabolic Syndrome.
    Kawada T
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2435. PubMed ID: 36372370
    [No Abstract]   [Full Text] [Related]  

  • 45. Prolactin in men's health and disease.
    Bolyakov A; Paduch DA
    Curr Opin Urol; 2011 Nov; 21(6):527-34. PubMed ID: 21941183
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between Nonalcoholic Fatty Liver and Gensini Score in Patients with Coronary Heart Disease: A Cross-Sectional Study.
    Wang P; Qiang H; Song Y; Dang Y; Luan H; Cao L; Cui Q; Tian G
    Cardiology; 2019; 144(3-4):90-96. PubMed ID: 31665722
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Macroprolactinemia in women with hyperprolactinemia: a 10-year follow-up.
    Radavelli-Bagatini S; Lhullier FL; Mallmann ES; Spritzer PM
    Neuro Endocrinol Lett; 2013; 34(3):207-11. PubMed ID: 23685418
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nonalcoholic fatty liver disease and cardiovascular risk in children with obesity.
    Koot BG; de Groot E; van der Baan-Slootweg OH; Bohte AE; Nederveen AJ; Jansen PL; Stoker J; Benninga MA
    Obesity (Silver Spring); 2015 Jun; 23(6):1239-43. PubMed ID: 25960049
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of nonalcoholic fatty liver disease using magnetic resonance in obese children and adolescents.
    Benetolo PO; Fernandes MIM; Ciampo IRLD; Elias-Junior J; Sawamura R
    J Pediatr (Rio J); 2019; 95(1):34-40. PubMed ID: 29438686
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypothalamic-pituitary function in diverse hyperprolactinemic states.
    Boyar RM; Kapen S; Finkelstein JW; Perlow M; Sassin JF; Fukushima DK; Weitzman ED; Hellman L
    J Clin Invest; 1974 Jun; 53(6):1588-98. PubMed ID: 4208470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hyperprolactinemia: pathophysiology and therapeutic approach.
    Capozzi A; Scambia G; Pontecorvi A; Lello S
    Gynecol Endocrinol; 2015 Jul; 31(7):506-10. PubMed ID: 26291795
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Paradoxical prolactin response to growth hormone-releasing hormone in a patient with hyperprolactinemia and empty sella.
    Imai Y; Shimizu T; Sawano S; Ozawa Y; Watanabe T; Shishiba Y
    Endocrinol Jpn; 1991 Apr; 38(2):183-6. PubMed ID: 1752237
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spontaneous partial empty sella. A study of 41 cases.
    Jara-Albarrán A; Bayort J; De Juan M; Benito C
    Exp Clin Endocrinol; 1984 Mar; 83(1):63-72. PubMed ID: 6539215
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
    Chun HS; Lee M
    Clin Mol Hepatol; 2023 Apr; 29(2):377-380. PubMed ID: 36907573
    [No Abstract]   [Full Text] [Related]  

  • 56. Sarcopenic Obesity, the Possible Culprit for Nonalcoholic Fatty Liver Disease or Fibrosis.
    Kang SH; Yoon EL
    Gut Liver; 2023 Jan; 17(1):8-9. PubMed ID: 36636885
    [No Abstract]   [Full Text] [Related]  

  • 57. Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else.
    Cho A; Vila G; Marik W; Klotz S; Wolfsberger S; Micko A
    Front Endocrinol (Lausanne); 2022; 13():901385. PubMed ID: 36147567
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.
    Hong JW; Lee MK; Kim SH; Lee EJ
    Endocrine; 2010 Feb; 37(1):140-7. PubMed ID: 20963563
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced Growth Hormone Secretion is Associated with Nonalcoholic Fatty Liver Disease in Obese Children.
    Liang S; Yu Z; Song X; Wang Y; Li M; Xue J
    Horm Metab Res; 2018 Mar; 50(3):250-256. PubMed ID: 29341046
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Subclinical hypothyroidism as a risk factor for the development of cardiovascular disease in obese adolescents with nonalcoholic fatty liver disease.
    Sert A; Pirgon O; Aypar E; Yilmaz H; Odabas D
    Pediatr Cardiol; 2013 Jun; 34(5):1166-74. PubMed ID: 23344895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.